iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (VEGAS)
Osteosarcoma, Neuroblastoma
About this trial
This is an interventional treatment trial for Osteosarcoma focused on measuring Osteosarcoma, T-Cells, varicella zoster virus (VZV), GD2, Neuroblastoma
Eligibility Criteria
Inclusion Criteria:
Procurement:
- Diagnosis of relapsed or refractory osteosarcoma OR relapsed or refractory high risk neuroblastoma not responsive to standard treatment.
- Either previously infected with varicella zoster virus(VZV; chicken pox) or previously vaccinated with VZV vaccine
- Karnofsky/Lansky score of greater than or equal to 50
- Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent
Treatment:
- Diagnosis of relapsed or refractory osteosarcoma OR relapsed or refractory high risk neuroblastoma not responsive to standard treatment.
- Recovered from the acute toxic effects of all prior chemotherapy
- Karnofsky/Lansky score of greater than or equal to 50
- Bilirubin less than or equal to 3x upper limit of normal, AST less than or equal to 5x upper limit of normal, Serum creatinine less than or equal to 2x upper limit of normal, Hgb greater than or equal to 7.0 g/dl, ANC>500/uL, platelets > 50,000/uL
- Pulse oximetry of greater than or equal to 90% on room air
- Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. Male partner should use a condom.
- Available autologous transduced cytotoxic T lymphocytes with greater than or equal to 20% expression of GD2 CAR and killing of GD2-positive targets greater than or equal to 20% in cytotoxicity assay
- Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent
Exclusion Criteria:
Procurement:
• Known primary immune deficiency or HIV positivity
Treatment:
- Severe intercurrent infection
- Known primary immune deficiency or HIV positivity
- Pregnant or lactating
- History of hypersensitivity reactions to murine protein-containing products
- Known allergy to VZV vaccine
Sites / Locations
- Houston Methodist Hospital
- Texas Children's Hospital
Arms of the Study
Arm 1
Experimental
GD2 T cells plus VZV vaccine
In this study we will be administering from 1 x 10^6 to 1 x 10^9 transduced autologous VZV-specific CTLs, derived from VZV-specific memory T cells, so there will be no risk of alloreactivity. 6.1.1 Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m2/day followed by Fludarabine 30 mg/m2/day.